Results 1 to 10 of about 1,815 (184)

Post‐hoc analysis of the tofogliflozin post‐marketing surveillance study (J‐STEP/LT): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMI [PDF]

Journal of Diabetes Investigation
Aims/Introduction Patients with type 2 diabetes are at high risk of developing steatotic liver disease (SLD). Weight loss has proven effective in treating metabolic dysfunction‐associated steatotic liver disease (MASLD) in obese patients with type 2 ...
Hiroyuki Uchinuma, Mitsunori Matsushita, Masaya Tanahashi, Hideki Suganami, Kazunori Utsunomiya, Kohei Kaku, Kyoichiro Tsuchiya   +6 more
doaj   +4 more sources

Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats [PDF]

Cells
Background: Liver cirrhosis leads to portal hypertension (PH) with capillarization of liver sinusoidal endothelial cells (LSECs), although drug treatment options for PH are currently limited.
Shohei Asada, Kosuke Kaji, Norihisa Nishimura, Aritoshi Koizumi, Takuya Matsuda, Misako Tanaka, Nobuyuki Yorioka, Shinya Sato, Koh Kitagawa, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji   +11 more
doaj   +5 more sources

Tofogliflozin ameliorates cardiotoxin induced skeletal muscle injury and fibrosis in obesity [PDF]

Scientific Reports
Obesity impairs muscle function through effects on lipid metabolism, systemic inflammation, and insulin resistance, leading to muscle loss and reduced regeneration.
Muhammad Bilal, Nguyen Quynh Phuong, Tomonobu Kado, Jianhui Liu, Le Duc Anh, Sana Khalid, Muhammad Rahil Aslam, Memoona, Ayumi Nishimura, Yoshiko Igarashi, Yoshiyuki Watanabe, Waseem Abbas, Maki Yokoyama, Yasuhiro Onogi, Kenichi Hirabayashi, Seiji Yamamoto, Kunimasa Yagi, Marsel Lino, Isao Usui, Masaru Kato, Shiho Fujisaka, Allah Nawaz, Kazuyuki Tobe   +22 more
doaj   +3 more sources

The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease [PDF]

Gastroenterology Insights, 2022
The increasing number of patients with fatty liver disease is a major health problem. Fatty liver disease with metabolic dysfunction has been recognized as nonalcoholic fatty liver disease (NAFLD).
Takeshi Goya, Koji Imoto, Shigeki Tashiro, Tomomi Aoyagi, Motoi Takahashi, Miho Kurokawa, Hideo Suzuki, Masatake Tanaka, Masaki Kato, Motoyuki Kohjima, Yoshihiro Ogawa   +10 more
doaj   +2 more sources

Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: The TOP‐STAR study [PDF]

Journal of Diabetes Investigation
Aim Nocturia impairs the quality of life in patients with type 2 diabetes mellitus. Although sodium glucose co‐transporter 2 inhibitors (SGLT2i) such as tofogliflozin increase urine volume, their impact on nocturia, in conjunction with dietary salt ...
Hanako Nakajima, Hiroshi Okada, Akinori Kogure, Takafumi Osaka, Takeshi Tsutsumi, Masayoshi Onishi, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Shinichi Mogami, Akane Kitamura, Michiyo Ishii, Naoto Nakamura, Akio Kishi, Sato Eiko, Masahide Hamaguchi, Michiaki Fukui   +15 more
doaj   +2 more sources

Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study (RESTORE‐nephropathy study) [PDF]

Journal of Diabetes Investigation
Aims/Introduction The mechanisms of the renoprotective effects of sodium‐glucose cotransporter 2 inhibitors are unknown. This study aimed to explore the effect and mechanism of tofogliflozin on urinary albumin by administration, withdrawal, and re ...
Ayako Shigeta, Masami Tanaka, Shu Meguro, Jiro Morimoto, Takatoshi Imai, Akira Yamauchi, Yasuhiko Kanazawa, Toshihide Kawai, Koichiro Azuma, Satoru Yamada, Sho Endo, Hiroshi Itoh, Kaori Hayashi   +12 more
doaj   +2 more sources

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial

Hepatology Communications, 2022
The incidence of nonalcoholic fatty liver disease (NAFLD) has recently increased and is related to obesity and the associated surge in type 2 diabetes mellitus (T2DM) and metabolic syndromes.
Masato Yoneda, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Takaomi Kessoku, Kento Imajo, Asako Nogami, Masataka Taguri, Hiroyuki Kirikoshi, Satoru Saito, Atsushi Nakajima   +10 more
doaj   +3 more sources

Effect of tofogliflozin on cardiac sympathetic nerve activity in type 2 diabetes mellitus patients with heart failure (TARGET-HF): rationale and design of the single-arm intervention trial [PDF]

Cardiovascular Diabetology. Endocrinology Reports
Background Cardiac sympathetic nervous dysfunction is linked to poor prognosis in heart failure with reduced ejection fraction (HFrEF), and patients with HFrEF complicated by type 2 diabetes mellitus (T2DM) represent a particularly high risk.
Takahiro Okumura, Yasuko K Bando, Satoshi Isobe, Naotoshi Fujita, Fusako Sera, Yuki Ikeda, Ayumu Yajima, Toshiyuki Nagai, Hiroaki Hiraiwa, Ryota Morimoto, Toshihisa Anzai, Koichi Node, Junya Ako, Yasushi Sakata, Toyoaki Murohara   +14 more
doaj   +2 more sources

Differential Effects of SGLT-2 Inhibitors on Liver Function and Nocturia in Patients with Type 2 Diabetes: A Randomized Controlled Trial [PDF]

Diabetes, Metabolic Syndrome and Obesity
Tetsuya Kawahara,1,2 Mikio Toda,1 Maiko Kanagawa,3 Nagahiro Toyama,3 Gen Suzuki,4 Chie Kawahara,2 Tetsuya Inazu5 1Division of Endocrinology and Metabolism, Shinkomonji Hospital, Kitakyushu, 800-0057, Japan; 2First Department of Internal Medicine ...
Kawahara T, Toda M, Kanagawa M, Toyama N, Suzuki G, Kawahara C, Inazu T   +6 more
doaj   +2 more sources

Tofogliflozin attenuates renal lipid deposition and inflammation via PPARα upregulation mediated by miR-21a impairment in diet-induced steatohepatitic mice [PDF]

Endocrine Journal
We previously demonstrated hepatic, cardiac, and skin inflammation in a high-fat diet-induced steatotic liver disease (SLD) model. However, the molecular mechanism in the kidneys in this model remains unclear.
Sae Nishihara, Masahiro Koseki, Katsunao Tanaka, Takashi Omatsu, Ayami Saga, Hiroshi Sawabe, Hiroyasu Inui, Takeshi Okada, Tohru Ohama, Daisuke Okuzaki, Yoshihiro Kamada, Masafumi Ono, Makoto Nishida, Mikio Watanabe, Yasushi Sakata   +14 more
doaj   +2 more sources